Bavencio Archives -

Last year, NICE said that Merck KGaA/Pfizer’s Bavencio was too expensive for routine in NHS use as a

NICE reverses stance on Merck’s Bavencio for bladder cancer

https://pharmaphorum.com/news/nice-reverses-stance-on-mercks-bavencio-for-bladder-cancer/

Scotland backs Bavencio for bladder cancer after NICE says no

Phil Taylor Bavencio, bladder cancer, Merck KGaA, NHS, NICE, Pfizer, Scotland, Scottish Medicines Consortium, urothelial carcinoma 0 Comment

Patients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance

Scotland backs Bavencio for bladder cancer after NICE says no

https://pharmaphorum.com/news/scotland-backs-bavencio-for-bladder-cancer-after-nice-says-no/

News/ News/ Oncology

NICE says no to Merck Serono’s Bavencio in bladder cancer

Phil Taylor Bavencio, bladder cancer, checkpoint inhibitors, HEOR, immuno-oncology, Merck KGaA, Oncology, urothelial carcinoma 0 Comment

Merck Serono’s Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer

NICE says no to Merck Serono’s Bavencio in bladder cancer

https://pharmaphorum.com/news/nice-says-no-to-merck-seronos-bavencio-in-bladder-cancer/

News/ News/ Oncology

Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

Phil Taylor Bavencio, bladder cancer, checkpoint inhibitors, immuno-oncology, Merck KGaA, Oncology, Pfizer, urothelial carcinoma 0 Comment

Pfizer and partner Merck KGaA now have approval on both sides of the Atlantic for their checkpoint inhibitor

Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

https://pharmaphorum.com/news/merck-pfizer-get-eu-nod-for-bavencio-as-bladder-cancer-maintenance/

Keeping up the PACE at the Scottish Medicines Consortium

Market Access/ News/ News

Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancer

Phil Taylor Bavencio, immuno-oncology, Inlyta, Merck KGaA, Oncology, Pfizer, renal cell carcinoma, Scottish Medicines Consortium 0 Comment

The Scottish Medicines Consortium (SMC) backed NHS use of nine new medicines at its meeting this week, including

Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancer

https://pharmaphorum.com/news/scotland-backs-merck-pfizers-bavencio-combo-for-kidney-cancer/

News/ News/ Oncology

FDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancer

Richard Staines AstraZeneca, Bavencio, bladder cancer, cancer, immunotherapy, Roche 0 Comment

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with

FDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancer

https://pharmaphorum.com/news/fda-approves-pfizer-merck-kgaas-bavencio-in-first-line-bladder-cancer/

News/ News/ Oncology

Merck, Pfizer’s Bavencio flunks head and neck cancer trial

Phil Taylor Bavencio, head and neck cancer, immuno-oncology, Merck KGaA, Oncology, Pfizer 0 Comment

Merck KGaA and Pfizer’s checkpoint inhibitor Bavencio has failed a phase 3 trial in head and neck cancer,

Merck, Pfizer’s Bavencio flunks head and neck cancer trial

https://pharmaphorum.com/news/merck-pfizers-bavencio-flunks-head-and-neck-cancer-trial/

News/ News/ Sales and Marketing

Mavenclad helps Merck shrug off Rebif decline in MS

Phil Taylor Bavencio, Mavenclad, Merck KGaA, multiple sclerosis 0 Comment

Accelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in

Mavenclad helps Merck shrug off Rebif decline in MS

https://pharmaphorum.com/news/mavenclad-helps-merck-shrug-off-rebif-decline-in-ms/

News/ News/ Oncology

Merck and Pfizer’s Bavencio approved for renal cell carcinoma

George Underwood Bavencio, immunotherapy, Merck KGaA, Pifzer, renal cell carcinoma 0 Comment

Merck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta

Merck and Pfizer’s Bavencio approved for renal cell carcinoma

https://pharmaphorum.com/news/merck-and-pfizers-bavencio-approved-for-renal-cell-carcinoma/

Trending

Bavencio

Login